Redx Pharma Ltd is a Liverpool-based bioscience startup focused on early-stage drug development using a platform called Redox Switch™ to rapidly assess and advance modified drug candidates. The company structurally modifies existing classes of drugs to create new proprietary medicines and has a pipeline targeting cardiovascular disease, influenza, antibiotics and neuropathic pain. In the reported transaction Redx acquired the assets of Bradford Pharma Ltd and will take over its operation at Merseybio, the University of Liverpool incubator. Redx received a £1.9m investment from public and private sources to support its platform and programs. Investors named in the article include the NWDA’s Northwest Interim Venture Capital Fund (managed by YFM Private Equity and funded by the ERDF), venture capitalist Jon Moulton, Acceleris and other regional backers. The management team is led by CEO Dr Neil Murray; the board is chaired by Dr Peter Jackson, with Dr Derek Lindsay as CTO and Norman Molyneux as CFO.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2010